Results 11 to 20 of about 65,156 (262)
Eosinophilic granulomatosis with polyangiitis: overcoming diagnostic obstacles and exploring pharmacotherapeutic approaches [PDF]
Exploration of ImmunologyEosinophilic granulomatosis with polyangiitis (EGPA) is an uncommon form of necrotizing vasculitis that affects the respiratory system and other organs, characterized by asthma, eosinophilia, and multiple organ involvement that complicates the diagnosis ...
Priya Komre +4 more
doaj +1 more source
Allergology International, 2002 Background: Both a recombinant soluble form of the high-affinity IgE receptor α subunit (rsFcεRIα) and anti-IgE antibody have been shown to be involved in the regulation of IgE synthesis.
Keiichi Kajiwara +2 more
doaj +1 more source
Advances in anti-IgE therapy. [PDF]
Biomed Res Int, 2015 Omalizumab depletes free IgE in the blood and interstitial space and inhibits IgE binding to FcεRI on basophils, mast cells, and dendritic cells. We stopped omalizumab treatment after four years. Recurrences of urticaria symptoms were found to be higher in patients with chronic urticaria than recurrences of asthmatic symptoms in severe persistent ...
Yalcin AD.
europepmc +4 more sources
Differential effects of the Toll-like receptor 2 agonists, PGN and Pam3CSK4 on anti-IgE induced human mast cell activation. [PDF]
PLoS ONE, 2014 Mast cells are pivotal in the pathogenesis of allergy and inflammation. In addition to the classical IgE-dependent mechanism involving crosslinking of the high-affinity receptor for IgE (FcεRI), mast cells are also activated by Toll-like receptors (TLRs)
Yangyang Yu +6 more
doaj +1 more source
Evolution of anti-IgE treatment [PDF]
Cellular & Molecular Immunology, 2015 The central role played by IgE antibodies in the pathophysiology of allergic diseases makes anti-IgE treatment of paramount importance. However, the development of anti-IgE drugs has taken more than two decades, from the first in vitro experiments in the 1970s to the availability of omalizumab as a safe and effective agent.1 Omalizumab was evaluated in
Cristoforo, Incorvaia, Marina, Mauro
openaire +2 more sources
Real‐life effectiveness of biological therapies on symptoms in severe asthma with comorbid CRSwNP
Clinical and Translational Allergy, 2021 Background We aimed to evaluate the effectiveness of different antibody therapies on nasal polyp symptoms in patients treated for severe asthma. Methods We performed a retrospective analysis of patients with severe asthma and comorbid CRSwNP who were ...
Carlo Mümmler +10 more
doaj +1 more source
Detection of anti-IgE anti-FcεRI α chain auto-antibodies in patients with atopic dermatitis
Allergology International, 2000 Anti-IgE and anti-FcεRI α chain auto-antibodies have been detected in the sera of atopic and non-atopic subjects; however, the biological activity of these auto-antibodies is still unclear.
Satoru Hayashi +5 more
doaj +1 more source
Immunity, Inflammation and Disease, 2022 Introduction Mast cells are regarded as a kind of classical anaphylaxis cells. However autoimmune diseases and allergic reactions have many similarities or overlaps.
Yuping Wang +5 more
doaj +1 more source
Journal of Immunology Research, 2019 Background. Chronic spontaneous urticaria (CSU) is a heterogeneous disease with some frequent comorbidities like autoimmune diseases, drug reactions, and inducible urticaria.
Jorge Sánchez +2 more
doaj +1 more source
Bispecific T-Cell Engagers Targeting Membrane-Bound IgE
Biomedicines, 2021 The increased incidence of allergies and asthma has sparked interest in IgE, the central player in the allergic response. Interaction with its high-affinity receptor FcεRI leads to sensitization and allergen presentation, extracellular membrane-proximal ...
Aleksandra Rodak +6 more
doaj +1 more source